Search 

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Brace Pharmaceuticals is based in Rockville, MD, and is a strategic investment company formed by Brazil-based pharma company EMS S/A. Brace investment structure varies depending on a company’s development stage; for early-stage opportunities Brace typically makes equity investments and may syndicate with other investors, whereas for clinical-stage opportunities Brace is more likely to form strategic partnerships that involve rights to an asset. Brace is open to considering therapeutic opportunities globally, but only if the company is pursuing the US market.

Brace Pharmaceuticals invests in therapeutics; about 80% of the firm’s investments are in clinical-stage assets, with a preference for companies with some human proof-of-concept data; the remaining 20% of investments are made in preclinical opportunities. Drug-device combinations will also be considered, but Brace does not invest in diagnostics. The firm will invest in both small and large molecules, and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases and primary care indications (such as influenza) will not be considered.

Cavidi is a Swedish based diagnostic company that has developed a novel method for measuring HIV viral load in patients recieving anti-retroviral therapy for treatment of HIV. Viral load is a critical indicator of the effectiveness of HIV therapy, and has been the standard of care in the developed world for many years. Just recently the World Health Organization (WHO) updated its recommendations to include viral load for patients in the developing world where the vast majority of HIV patients exists, and a large influx of international funding has significantly increased aceess to HIV drugs. The Cavidi method is novel in that it measures the viral enzyme reverse transcriptase (RT), and not viral nucleic acid (RNA) by polymerase chain reaction (PCR). The Cavidi method is not subject to the logistical challenges of PCR such as contamination risk. The Cavidi RT assay is much less expensive and can be performed in labs that lack the sophisitication to perform technologies such as PCR. Therfore, the Cavidi assay significantly improves access to this vitally important technology. For the past several years a manual version of the Cavidi technology has been utilized in laboratories in the developing world. The performance of the assay has been validated vs the industry leading PCR methods in many peer review publications. The company is now seeking funding to develop an automated version of the assay that will make it more widely adaptable to many laborartories. 

CDRD Ventures Inc. (CVI) is the commercialization vehicle of the Centre for Drug Research and Development (CDRD), Canada's national drug development and commercialization center that was founded in 2007 and is based in Vancouver, Canada. CVI seeks to advance promising drug development projects from CDRD using internal funds and through partnerships with international pharmaceutical companies, venture capital firms, biotech companies, and other funding agencies. CVI also seeks to in-license technologies from industry or non-CDRD affiliated research institutions. The firm considers both small molecule and biologic innovative technologies in virtually any therapeutic area.

Regeneration Through Innovation

Celling Biosciences is dedicated to researching and developing the future of healing through regenerative medicine and the clinical use of autologous regenerative cells to facilitate the body’s capacity to heal itself. Through our patented Celling therapies and our Institutes of Regenerative Medicine, Celling Biosciences is moving the science of healing forward and redefining the global medical landscape.